Under the terms of the partnership, Orexia Therapeutics will be responsible for preclinical research activities, clinical development and commercialization of future product candidates discovered under the collaboration.
Meanwhile, Schrodinger will receive an upfront software access payment and may become eligible to receive certain preclinical, development, regulatory and commercial milestone payments, as well as low single-digit royalties on global net sales, according to a statement.
|Jazz Pharma Doses First Patient in Late-Stage Combo ...|
|Update: Barnes & Noble Education Fiscal Q2 Gains Tra...|
|Bitcoin Miner Griid Infrastructure to go Public in M...|
|--Saratoga Investment Raises Quarterly Dividend to $...|
|StoneCo Shares Decline Following Banco Santander Dow...|